Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2021

View Archived Issues

Patient recruitment ongoing in phase I study of CAR.B7-H3 T-cell therapy in ovarian cancer

Intra-Cellular plans to develop ITI-1284 for dementia and depressive disorders in the elderly

REGN-3048 plus REGN-3051 show promise for treatment or prophylaxis of MERS-CoV infection

Targeting of neoplastic progenitors as new therapeutic strategy in AML

Xencor and UCLA collaborate to develop novel therapeutic antibodies

Data from proof-of-concept OSCAR study of otilimab in hospitalized patients with COVID-19

Promising first cohort data from phase II/III study of DSTAT in severe COVID-19

Altimmune initiates enrollment in phase I study of AdCOVID intranasal COVID-19 vaccine candidate

ESSA Pharma and Astellas collaborate to investigate EPI-7386 plus enzalutamide in mCRPC

Initiation of phase IIa study evaluating BGE-117 in elderly with unexplained anemia

Repure Life Science patents p300 inhibitors

Well Marker Bio presents new MST1R inhibitors

Gene variants can increase fat, decrease cardiometabolic risk

Janssen Pharmaceutica synthesizes new compounds for HBV infection

First patient dosed in phase III study of eftansomatropin alfa in China

Amgen discovers new KIF18A inhibitors

Italian researchers present new PTPN11 inhibitors

MicroRNA switch therapy self-assembles into nanoparticles to treat atherosclerosis

Compugen presents updated results from phase I study of COM-701

Chromosome organization machinery linked to DNA repair

First patient dosed in phase I/II study of KB-0742

Targeting EPIC1-EZH2 axis as potential new immunotherapy strategy in cancer

Pilot trial of lentivirus-mediated enzyme gene therapy for the treatment of Fabry disease

FDA grants accelerated approval to Amondys 45 for Duchenne muscular dystrophy

IDMC recommends stopping enrollment of placebo group in phase III outpatient trial of REGEN-COV

Aivita completes phase I study of AV-COVID-19

SARPAC study of inhaled sargramostim in COVID-19 meets primary endpoint

NIAID to conduct phase I study of mRNA-1273.351 for SARS-CoV-2 variant B.1.351

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...